O bstructive sleep apnea (OSA) is highly prevalent, affecting 4% of men and 2% of women who meet a disease-defining threshold of at least 5 episodes of apnea or hypopnea per hour of sleep (apnea-hypopnea index [AHI] ≥5) and excessive daytime sleepiness.1 Continuous positive airway pressure (CPAP), a technique that pneumatically supports the upper airway, is a therapeutic mainstay for OSA. It has been shown to reduce the AHI, improve sleepiness and quality of life, and reduce cardiovascular risk.2,3 Despite demonstrable benefits and technological equipment advances, compliance with CPAP therapy varies, with 29% to 83% of patients using CPAP for less than 4 hours a night in various studies. 4